Followers | 144 |
Posts | 27709 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, September 03, 2020 12:52:49 PM
By Kate Hudson -September 3, 2020
Throughout its many years of operation, Can-Fite Biopha (NYSEAMERICAN:CANF) has been addressing multi-billion dollar markets. Its primary target has been the advancement of cancer treatments, inflammatory diseases, and, most recently, COVID-19. A majority of the company’s drugs have demonstrated an excellent safety profile, having been used in over 1,500 patients in clinical studies to date.
Can-Fite continues to count its milestones after receiving a notification of its intent to grant a patent for Namodenoson in the Treatment of non-alcoholic steatohepatitis (NASH) from the European Patent Office. The patent was justified by a strong safety profile demonstrated by Namodenoson and the fact that it also met in the Treatment of NASH and non-alcoholic fatty liver disease (NAFLD).
Licensing and Distribution Agreements for Namodenoson
NAFLD and NASH are some of the heaviest disease burdens in Europe today. Epidemiology studies indicate that the two’s dominance stands between 29-37% and 16-45%, respectively, among the general population. This is a worrisome situation, indeed. Having completed a Phase II study and with the patent notification, Dr. Pnina Fishman, the CEO of Can-Fite BioPharma, says that it is the high time looked for potential distribution partners.
The Israeli-based company has been collaborating with some of the largest researchers from the US NIH and also from the Leiden University in the Netherlands. Meanwhile, patents for Namodenoson will be in Korea and the US. Can-Fite has also received licensing and distribution agreements for Namodenoson in China.
The Licensing of Piclidenoson for the Treatment of Autoimmune Diseases
Piclidenoson (CF101) is an oral drug and has undergone successful testing in animal models. The drug has been indicated as a disease-modifying anti-inflammatory drug in Rheumatoid Arthritis (RA) patients from two Phase II studies. The says it has dosed over 1,400 patients with the drug in prior trials, and after a 28-day study with 40 patients on board, Piclidenoson has been cleared for a Phase II study in the Treatment of COVID-19.
This is a pilot trial in a population of hospitalized patients and will be assessing efficacy through standard measures of clinical and respiratory status. The drug is expected to be an ideal candidate in treating the complications of COVID-19, given its unique combination of anti-inflammatory effect.
https://biopharmajournal.com/2020/09/03/the-european-patent-office-notifies-can-fite-biopha-nyseamericancanf-of-its-patent-grant-for-namodenoson-in-the-treatment-of-nash/
Recent CANF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 11:05:13 AM
- Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis • GlobeNewswire Inc. • 09/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 11:07:52 AM
- Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:08 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/06/2024 08:30:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 08:18:30 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/30/2024 08:18:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 08/30/2024 08:16:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/30/2024 08:15:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 12:46:20 PM
- Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies • GlobeNewswire Inc. • 08/29/2024 12:15:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/12/2024 10:45:11 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2024 10:07:53 AM
- Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds • GlobeNewswire Inc. • 08/08/2024 11:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 11:03:27 AM
- Can-Fite Provides Namodenoson Patent Update • GlobeNewswire Inc. • 07/29/2024 11:00:00 AM
- Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8 • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2024 11:05:26 AM
- Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson • GlobeNewswire Inc. • 07/01/2024 11:00:00 AM
- Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix • Business Wire • 06/28/2024 11:00:00 AM
- Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver • Business Wire • 06/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/10/2024 11:05:22 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM